GLP-1 Receptor Agonists Improve Weight, Blood Sugar, and Cholesterol in Heart Transplant Patients | Research

The takeaway

In 74 heart transplant recipients, GLP-1 receptor agonists (primarily semaglutide) significantly reduced BMI, HbA1c, LDL cholesterol, and insulin requirements over a median follow-up of 383 days with good tolerability and minimal immunosuppression changes.

BMI dropped from 33.3 to 31.5 in transplant patients
Heart transplant recipients on GLP-1 agonists showed significant weight loss alongside improved blood sugar, cholesterol, and reduced insulin needs over about one year of treatment.

What the researchers found

Over a median follow-up of 383 days, 74 heart transplant recipients on GLP-1 receptor agonists showed significant improvements: mean BMI decreased from 33.3 to 31.5 kg/m² (p < 0.0001), HbA1c from 7.3% to 6.7% (p = 0.005), LDL cholesterol from 78.6 to 70.3 mg/dL (p = 0.018), and basal insulin daily dose from 32.6 to 24.8 units (p = 0.0002).

The majority (76%) received semaglutide. Primary indications were T2DM alone (45%) or combined T2DM and obesity (35%). The drugs were well tolerated and rarely required adjustments to immunosuppression dosing — a critical safety consideration in transplant patients.

Why it matters

Heart transplant recipients have high rates of metabolic complications — diabetes, obesity, and high cholesterol — largely driven by their immunosuppressive medications. Yet there has been limited evidence on whether GLP-1 drugs are safe to use alongside anti-rejection drugs. This study provides real-world evidence that these peptide therapies are both effective and well tolerated in this vulnerable population, potentially improving long-term transplant outcomes by addressing major cardiovascular risk factors.

How the study worked

Retrospective review of all adult heart transplant recipients at a large-volume transplant center who received GLP-1 receptor agonists for at least 1 month post-transplant. Cardiometabolic parameters (BMI, HbA1c, lipid panel, eGFR, NT-proBNP) were compared before drug initiation and at most recent follow-up. Changes in immunosuppression dosing and adverse effects leading to discontinuation were also evaluated.

What this study cannot tell us

This is a retrospective, single-center study without a control group, making it impossible to separate GLP-1 effects from other concurrent lifestyle or medication changes. The cohort was moderately sized (n=74) and may not represent all transplant populations. Long-term outcomes beyond the study period, including effects on graft survival and rejection rates, were not assessed. Drug-drug interactions with immunosuppressants were monitored but not comprehensively characterized.

How to read the evidence

This is a retrospective, single-center observational study without a control group. While it provides valuable real-world safety and efficacy data in an understudied population, it ranks below prospective trials and randomized studies in the evidence hierarchy.

When this study was published

Published in 2024, this study is very current and addresses a timely question as GLP-1 agonist prescriptions surge worldwide. It fills an important evidence gap for transplant medicine where these drugs have been used cautiously due to limited data.

The bigger picture

This study addresses a growing need as transplant medicine intersects with the GLP-1 revolution. With millions of doses of semaglutide and similar drugs being prescribed, transplant clinicians need to know whether these medications are compatible with immunosuppressive regimens. This positive safety and efficacy signal could broaden GLP-1 agonist use to an underserved population that desperately needs metabolic management tools.

Questions still open

Do GLP-1 receptor agonists improve long-term graft survival in heart transplant patients by reducing cardiovascular risk factors?
Are there any long-term interactions between GLP-1 drugs and common immunosuppressants like tacrolimus or mycophenolate?
Could earlier initiation of GLP-1 agonists after transplant prevent the metabolic complications that typically develop in the first year?

Common questions

Why do heart transplant patients need weight loss and diabetes drugs?

After a heart transplant, patients must take immunosuppressive drugs for life to prevent organ rejection. Unfortunately, these medications — especially steroids and calcineurin inhibitors — commonly cause weight gain, diabetes, and high cholesterol. These metabolic problems increase the risk of heart disease in the transplanted heart, making effective treatment essential for long-term transplant success.

Is it safe to take GLP-1 drugs alongside anti-rejection medications?

This study suggests yes. Among 74 heart transplant patients who took GLP-1 receptor agonists (mostly semaglutide) for about a year, the drugs were well tolerated and rarely required changes to their immunosuppression dosing. However, as a retrospective study, it cannot rule out all potential interactions, and transplant patients should always be monitored closely when starting new medications.

Read the original research

Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.

Clinical transplantation, 38(7), e15401

View on PubMed ↗Publisher’s paper ↗

Citation

Donald, Elena M; Driggin, Elissa; Choe, Jason; Batra, Jaya; Vargas, Fabian; Lindekens, Jordan; Fried, Justin A; Raikhelkar, Jayant K; Bae, David J; Oh, Kyung T; Yuzefpolskaya, Melana; Colombo, Paolo C; Latif, Farhana; Sayer, Gabriel; Uriel, Nir; Clerkin, Kevin J; DeFilippis, Ersilia M. (2024). Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.. Clinical transplantation, 38(7), e15401. https://doi.org/10.1111/ctr.15401